Regular Article
Pelvic and Paraortic Lymph Nodal Status in Advanced Ovarian Cancer and Survival

https://doi.org/10.1006/gyno.1999.5397Get rights and content

Abstract

Background. In order to analyze the prognostic role of node involvement in advanced ovarian cancer, we have analyzed data from a randomized clinical trial on advanced ovarian cancer.

Methods. Cases were 456 women who entered a randomized multicentric clinical trial comparing two cisplatin-based schemes of treatment after cytoreductive surgery for advanced stage III–IV ovarian cancer. They underwent selective pelvic and/or paraortic lymphadenectomy.

Results. A total of 161 (35.3%) cases had positive nodes. The frequency of positive nodes was statistically significantly higher in FIGO stage IV than in stage III. Also grade 3 tumors were more likely to have positive nodes than grade 1–2 tumors. No association was observed between nodal status and response to chemotherapy. The 3-year survival was 46.2 (standard error (SE) = 3.4 based on 147 deaths) and 44.6 (SE = 4.4, based on 84 deaths), respectively, in negative and positive node groups. The corresponding values, when the analysis was performed considering only subjects with residual tumor <1 cm or absent, after first-line cytoreductive surgery were 66.2 (SE = 5.7) and 62.4 (SE = 9.6).

Conclusions. We did not find any association between nodal status and survival. Particularly, nodal status was not a prognostic factor for survival in the subgroup of women with residual tumor <1 cm or absent after cytoreductive surgery.

References (12)

There are more references available in the full text version of this article.

Cited by (32)

  • Epithelial ovarian cancer

    2023, DiSaia and Creasman Clinical Gynecologic Oncology
  • Epithelial ovarian cancer

    2018, Clinical Gynecologic Oncology
  • Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer

    2012, Gynecologic Oncology
    Citation Excerpt :

    A recent retrospective review analyzing data from previous randomized trials demonstrated that a survival benefit may be associated with lymphadenectomy in advanced ovarian cancer patients [16]. However, other investigators have questioned the therapeutic efficacy of systematic lymphadenectomy [17,18]. The only randomized controlled trial (RCT) comparing systemic pelvic and para-aortic lymphadenectomy with resection of bulky nodes only demonstrated that systemic lymphadenectomy did not improve overall survival in advanced ovarian cancer [19].

  • Computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with ovarian cancer: A meta-analysis

    2012, European Journal of Radiology
    Citation Excerpt :

    Ovarian cancer is the fifth most common cause of cancer death and accounts for over half of all deaths related to gynecologic cancer [1]. Nodal metastases are common, particularly in advanced (stages III–IV) ovarian tumors, with an incidence of 35–78% [2,3]. Metastasis to lymph nodes has an important impact on the overall stage of ovarian cancer, on how these patients are treated and on the prognosis.

  • Epithelial Ovarian Cancer

    2012, Clinical Gynecologic Oncology: Eighth Edition
View all citing articles on Scopus
View full text